Mounjaro KwikPen transition complete: Lilly

Nicholas O’Donoghue 30/06/2025

Eli Lilly confirms that Mounjaro (tirzepatide) will no longer be available in vial presentations, after transitioning the product to a multi-dose, pre-filled pen Mounjaro manufacturer, Eli Lilly, has informed the Therapeutic Goods Administration (TGA) that vial preparations of the medication have now been exhausted. In a statement, the TGA noted that the “discontinuation only

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

This web site is intended for Australian pharmacy professionals and is not a substitute for independent professional advice. Information and interactions contained in this website are for information purposes only and are not intended to be used to diagnose, treat, cure or prevent any disease. Further the accuracy, currency and completeness of the information available on this web site cannot be guaranteed. APPco Pty Ltd, its affiliates and their respective servants and agents do not accept any liability for any injury, loss or damage incurred by use of or reliance on the information made available via or through ajp.com.au whether arising from negligence or otherwise.

Mounjaro KwikPen transition complete: Lilly

Previous APC calls time on CPD standards

Next Butler open to pharmacy vaping reforms

MENU

ajp.com.au

Previous APC calls time on CPD standards

Next Butler open to pharmacy vaping reforms

MENU

ajp.com.au

Tags

Hi there! 👋 Looks like you’re not logged in.